Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Total Non-Current Liabilities (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Total Non-Current Liabilities for 16 consecutive years, with $46.1 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 3.91% to $46.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $46.1 million through Dec 2025, down 3.91% year-over-year, with the annual reading at $46.1 million for FY2025, 3.91% down from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $46.1 million at Anika Therapeutics, up from $41.9 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $79.8 million in Q1 2021, with the low at $39.3 million in Q2 2025.
  • Average Total Non-Current Liabilities over 5 years is $55.7 million, with a median of $56.5 million recorded in 2022.
  • The sharpest move saw Total Non-Current Liabilities crashed 60.71% in 2021, then grew 13.39% in 2022.
  • Over 5 years, Total Non-Current Liabilities stood at $59.2 million in 2021, then grew by 6.72% to $63.2 million in 2022, then dropped by 8.24% to $58.0 million in 2023, then decreased by 17.22% to $48.0 million in 2024, then decreased by 3.91% to $46.1 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $46.1 million, $41.9 million, and $39.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.